Adaptive Biotechnologies Corporation (ADPT) - Stock Analysis
Last updated: Sep 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Adaptive Biotechnologies (ADPT) exhibits strong short-term momentum with a recent earnings beat, 52% YoY MRD revenue growth, raised guidance, and technical breakout above the upper Bollinger Band, complemented by favorable biotech sector tailwinds.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Persistent losses ⢠Rising leverage ⢠Strong liquidity ADPT has strong gross margins and improved liquidity, but persistent losses, negative cash flow, rising leverage, and expensive sales/book multiples make it a high-risk investment pending a credible path to profitability.
Price Behavior
Key Price Behavior Insights: ⢠Support Holding ⢠Weak Momentum ⢠Breakout Trigger Support Level: $24.20â$24.30 (then $23.60) Resistance Level: $24.90â$25.20 ADPT is bearish over the last month but holding $24.20â$24.30 support; a break below risks $23.60, while reclaiming $24.90â$25.20 would signal improving momentum.
Sentiment & News
Key News Insights: ⢠Major stake cuts ⢠Investor conference ⢠Founder startup Adaptive faces a cautious sentiment signal from major institutional selling, though its upcoming investor conference appearance may support visibility.
AI Summary
ADPT's $300M convertible shifts the thesis from survival to execution: investors should demand clear MRD-driven operating leverageârevenue outpacing opex and sustained cash-burn improvementâbecause its >12x sales valuation leaves little cushion for continued losses and future dilution.
Description
Adaptive Biotechnologies is a commercial-stage company that develops immune-based diagnostics and therapeutics, offering sequencing and clinical assays to detect and monitor cancer, infectious diseases and immune-related conditions. Its portfolio includes research and clinical immunosequencing products and laboratory diagnostics for minimal residual disease and past infection detection, and it supports life-science research, clinical diagnostics and drug discovery. The company maintains strategic collaborations with Genentech on neoantigen-directed T-cell therapies and with Microsoft on computational diagnostic efforts; it was incorporated in 2009 and is headquartered in Seattle, Washington.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 25 | Dec 2 | ADPT | Adaptive Biotechnologies Corporation | Adaptive Biotechnologies (ADPT) exhibits strong short-term momentum with a recent earnings beat, 52% YoY MRD revenue growth, raised guidance, and technical breakout above the upper Bollinger Band, complemented by favorable biotech sector tailwinds. | Closed | -8.0% |